Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag Olamine for CIT in Cervical Cancer
NCT05160857Unknown
- Sponsor
- The Second Hospital of Shanxi Medical University
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by The Second Hospital of Shanxi Medical University. Primary endpoint: Platelet index at 14 days. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT05160857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160857.